OncoNano Medicine
Texas-based OncoNano Medicine develops pH-activated compounds for cancer, Alzheimer's, and metabolic disorders.
Founded
2014Texas-based OncoNano Medicine develops pH-activated compounds for cancer, Alzheimer's, and metabolic disorders.
OncoNano Medicine, founded in Texas, is a clinical-stage biotechnology company focused on transforming cancer therapeutics through its proprietary nanotechnology platform. The company's core mission is to leverage pH-activated compounds to develop advanced therapeutics and imaging technologies for cancer, Alzheimer's, and metabolic disorders. OncoNano's flagship technology, the ON-BOARD™ polymeric micelle platform, aims to precisely deliver anti-tumor payloads to the tumor microenvironment, enhancing the efficacy and specificity of cancer treatments.
Notable affiliated individuals include scientific leaders and industry experts who contribute to OncoNano's innovative approach. The company has attracted significant investment from key venture capital firms, underscoring confidence in its technology. Among its achievements, OncoNano has developed a differentiated pipeline of novel therapies that have shown promise in preclinical and early clinical trials. The company's impact lies in its potential to revolutionize cancer treatment by improving targeting accuracy and reducing side effects, thereby enhancing patient outcomes.
Companies similar to OncoNano Medicine include Nanospectra Biosciences, Duo Oncology, NanoMedTrix and NanoValent Pharmaceuticals.
OncoNano Medicine was founded in 2014.
OncoNano Medicine's headquarters is located in Southlake, TX, US.
OncoNano Medicine's most recent funding round was for $18.4M (USD) in October 2021.
As of Oct 25, 2021, OncoNano Medicine has disclosed funding of $188.1M (USD). Undisclosed round amounts are excluded.
OncoNano Medicine has 29 employees as of Feb 5, 2024.
NanoValent Pharmaceuticals
